Replimune Group, Inc.

NASDAQ (USD): Replimune Group, Inc. (REPL)

Last Price

13.02

Today's Change

+1.17 (9.87%)

Day's Change

11.82 - 13.32

Trading Volume

1,451,605

Overview

Market Cap

980 Million

Shares Outstanding

75 Million

Avg Volume

846,883

Avg Price (50 Days)

12.19

Avg Price (200 Days)

9.90

PE Ratio

-4.28

EPS

-3.04

Earnings Announcement

06-Feb-2025

Previous Close

11.85

Open

12.07

Day's Range

11.825 - 13.32

Year Range

4.92 - 17.0

Trading Volume

1,451,605

Price Change Highlight

1 Day Change

9.87%

5 Day Change

24.24%

1 Month Change

5.51%

3 Month Change

8.41%

6 Month Change

29.68%

Ytd Change

3.66%

1 Year Change

65.65%

3 Year Change

-38.58%

5 Year Change

-27.55%

10 Year Change

-14.12%

Max Change

-14.12%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment